Jafron Biomedical Co Ltd (300529.SZ) stock: key figures, P/E, revenue and dividend

Health Care · Health Care Equipment · China · ISIN CNE100002995

Price
17.22 CNY
Market cap
13.75 bn CNY
P/E (2025)
25.81
P/S (2025)
6.84
Dividend yield
3.02 %
Net margin
26.48 %
Return on equity (ROE)
15.35 %
Return on assets (ROA)
9.85 %

Jafron Biomedical Co Ltd financials

Fiscal year20242025
Revenue2.68 bn CNY2.01 bn CNY
Gross profit2.16 bn CNY1.58 bn CNY
Operating income1.05 bn CNY739.52 m CNY
EBIT997.98 m CNY713.64 m CNY
Net income820.20 m CNY532.82 m CNY
Diluted EPS – continuing operations1.07 CNY0.67 CNY

Full history since 2011, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Jafron Biomedical Co Ltd

Jafron Biomedical Co.,Ltd. engages in the research, development, production, and sale of blood purification products for hemadsorption field worldwide. The company offers therapies for kidney, liver, and critical diseases, as well as poisoning. It also provides HA series disposable hemoperfusion cartridge; BS series disposable plasma bilirubin perfusion adsorption column; blood purification machine; and other products, such as JM hemodialyzer, DNA230, disinfectant, hemodialysis concentrate, resin bandage, online hemodialysis B powder bag/bucket, PGA absorbable suture with needle, syringe and infusion pumps. The company was founded in 1989 and is based in Zhuhai, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.